Production of powders for respiratory drug delivery

Supercritical Fluid Technology for Drug Product Development

Volumn , Issue , 2004, Pages 247-282

  Shekunov, Boris Y ^a  

^a Ferro Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27944508035     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293-304.
2. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG. Improved lungdelivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm Res 2002; 19:689-695.
3. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 84:379-385.
4. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1998; 1:394-398.
5. Beach S, Latham D, Sidgwick C, Hanna M, York P. Control ofthe physical formof salmeterol xinafoate. Org Process Res Dev 1999; 3:370-376.
6. Staniforth IN. Pre-formulation aspects of dry powder aerosols. Proceedings ofthe Conference on Respiratory Drug Delivery, Phoenix, AZ 1996; V:65-74.
7. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Surface-modifiedantiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologicallyeffective dose. Pharm Res 1998; 15: 1753–1759.
8. Lucas P, Anderson K, Potter UJ, Staniforth JN. Enhancement of small particlesize dry powder aerosol formulations using an ultra-low density additive. PharmRes 1999; 16:1643-1647.
9. Chew NYK, Chan HK. Effect of particle size and surface morphology on thedispersion of albumin powders. Proceedings of the Conference on Respiratory Drug Delivery, Palm Harbor, FL 2000; VII:619-622.
10. Bosquillon C, Lomby C, Preat V, Vanbever R. Influence of formulation excipientsand physical characteristics of inhalation dry powders on their aerosolisation performance. J Controlled Release 2001; 70:329-339.
11. Tee SK, Marriot C, Zeng XM, Martin GP. The use of different sugars as fine andcoarse carriers for aerosolised salbutamol sulphate. Int J Pharm 2000; 208: 111–123.
12. Steckel H, Thies J, Miil1ler BW. Micronizing of steroids for pulmonary deliveryby supercritical carbon dioxide. Int J Pharm 1997; 152:99-110.
13. Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Largeporous particles for sustained protection from carbachol-induced bronchoconstrictionin guinea pigs. Pharm Res 1999; 16:555-561.
14. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu Cc. Protein inhalation powders:spray drying vs spray freeze drying. Pharm Res 1999; 16:249-254.
15. Constantino HR, Firouzabadian L, Hogeland K, Wu C, Beganski C, Carrasquillo KG, Cordova M, Griebenow K, Zale SE, Tracy MA. Protein spray-freeze drying. Effect of atomisation conditions on particle size and stability. Pharm Res 2000; 17:1374-1383.
16. Yu ZC, Rogers TL, Hu JH, Johnston KP, Williams RO. Preparation and characterization of microparticles produced by a novel process: spray freezing into liquid. Eur J Pharm Biopharm 2002; 54:221-228.
17. Adjei AL, Qiu Y, Gupta PK. Bioavailability and pharmacokinetics of inhaleddrugs. In: Hickey AJ, ed. Inhalation Aerosols. New York: Marcel Dekker, 1996.
18. Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J Controlled Release 2001; 77: 117–129.
19. EI-Baseir MM, Kellaway IW. Poly (L-lactic acid) microspheres for pulmonarydrug delivery: release kinetics and aerosolisation studies. Int J Pharm 1998;175:135-145.
20. Steckel H, Müller BW. Metered-dose inhaler formulation of fluticasone-17-propionatemicronized with supercritical carbon dioxide using the alternativepropellent HFA-227. Int J Pharm 1998; 173:25-33.
21. Feeley JC, York P, Sumby BS, Dicks H, Hanna M. In vitro assessment of salbutamol sulphate prepared by micronisation and a novel supercritical fluid technique. Drug Delivery Lungs 1998; IX:196-199.
22. Feeley JC, York P, Sumby BS, Dicks H. Comparison of the surface properties ofsalbutamol sulphate prepared by micronisation and a supercritical fluid technique. J Pharm Pharmacol 1998; 50:54.
23. Feeley JC, Gilbert DJ, Palakodaty S, Walker SE, York P. Engineering of particlesize distributions for respiratory drug delivery by supercritical fluid processing. Proceedings of the Conference on Respiratory Drug Delivery, Palm Harbor, FL 2000; VII:357-360.
24. Shekunov BY, Feeley JC, Chow AHL, Tong HHY, York P. Aerosolization behaviour of micronised and supercritically-processed powders. J Aerosol Sci. In press.
25. Tong HHY. Ph.D thesis. Chinese University of Hong Kong, 2003.
26. Rehman MU. Ph.D thesis. University of Bradford, 2002.
27. Shekunov BY, Rehman M, Chow AHL, Tong HHY, York P. Production of crystalline powders for inhalation drug delivery using supercritical fluid technology. Proceedings of the 6th International Symposium on Supercritical Fluids, April 28–30, 2003, Versailles, France.
28. Rehman M, Shekunov BY, York P, Lechuga D, Miller D, Tan T, Colthorpe P. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci 2003. Submitted.
29. Velaga SP, Ghaderi R, Carlfors J. Preparation and characterization of hydrocortisoneparticles using a supercritical fluids extraction process. Int J Pharm2002; 231: 155–166.
30. Richardson CH, Chrystyn H, Won ICK, Walker S. Comparison of in-vitro performance of salbutamol sulphate manufactured by a supercritical fluid processmicronized salbutamol in a dry powder inhaler. AAPS PharmSci 2002; 4:T3197.
31. Tong HHY, Shekunov BY, York P, Chow AHL. Influence of polymorphism onthe surface energetics of salmeterol xinafoate crystallized from supercriticalfluids. Pharm Res 2002; 19:640-648.
32. York P, Hanna M. Particle engineering by supercritical fluid technologies forpowder inhalation drug delivery V. Proceedings of the Conference on Respiratory Drug Delivery, Phoenix, AZ, 1996:231-239.
33. Tong HHY, Shekunov BY, York P, Chow AHL. Characterisation of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 2001; 18:852-858.
34. Shekunov BY, Feeley JC, Chow AHL, Tong HHY, York P. Physical propertiesof supercritically-processed and micronised powders for respiratory drug delivery. KaNA Powder and Particles 2003; 20:178-187.
35. Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res 2002; 19: 1564–1571.
36. Rehman MU, Shekunov BY, York P, Colthorpe P. Solubility and precipitationof nicotinic acid in supercritical carbon dioxide. J Pharm Sci 2001; 90: 1570–1582.
37. Feeley JC, York P, Sumby BS, Dicks H. Determination of surface properties andflow characteristics of salbutamol sulphate, before and after micronisation. Int J Pharm 1998; 172:89-96.
38. Bisrat M, Moshashaee S, Nyqvist H, Dumirbuker M. Composition of matter. US patent application 6, 475, 524, 2000.
39. Shekunov BY, Bristow S, Chow AHL, Cranswick L, Grant DJW, York P. Formationofcomposite crystals by precipitation in supercritical CO2, Cryst Growth Design 2003; 3:603-610.
40. Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventionalsolvent evaporation method. J Pharm Sci 2002; 91:1948-1957.
41. Villa JA, Sievers RE, Huang ETS. Bubble drying to form fine particles fromsolutes in aqueous solutions. Proceedings of the 7th Meeting on Supercritical Fluids, Antibes/Juan-Les-Pins, France, 2000:83-85.
42. Yeo SD, Debenedetti PG, Patro SY, Przybycien TM. Secondary structure characterization of microparticulate insulin powders. J Pharm Sci 1994; 83:1651-1656.
43. Winters MA, Knutson BL, Debenedetti PG, Sparks HG, Przybycien TM, Stevenson CL, Prestrelski SJ. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci 1996; 85:586-594.
44. Moshashaee S, Bistrat M, Forbes RT, Nyqvist H, York P. Supercritical fluidprocessing of proteins. I. Lysozyme precipitation from organic solution. Eur J Pharm Sci 2000; 11:239-245.
45. Snavely WK, Subramaniam B, Rajewski RA, Defelippis MR. Micronization ofinsulin from halogenated alcohol solution using supercritical carbon dioxide asan antisolvent. J Pharm Sci 2002; 91:2026-2039.
46. Bustami RT, Chan HK, Dehghani F, Foster NR. Generation of micro-particlesof proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res 2000; 17:1360-1366.
47. Bustami RT, Chan HK, Foster NR. Aerosol delivery of protein powders processed by supercritical fluid technology. Proceedings of the Conference on Respiratory Drug Delivery VII, Palm Harbor, FL, 2000:611-613.
48. Tservistas M, Levy MS, Lo-Yim MYA, O'Kennedy RD, York P, Humphreys GO, Hoare M. The formation of plasmid DNA loaded pharmaceutical powdersusing supercritical fluid technology. Biotechnol Bioeng 2001; 72:12-18.
49. Hollowood ME, Humphreys GO, Shekunov BY, Sloan R, York P. Formation of protein particles in supercritical fluids. Proceedings of the 7th International Conference on Crystallization of Biological Macromolecules, Granada, Spain, 1998:209.
50. Falk R, Randolph TW, Meyer JD, Kelly RM, Manning MC. Controlled releaseofionic compounds from poly (L-lactide) microspheres produced by precipitationwith a compressed antisolvent. J Controlled Release 1997; 44:77-85.
51. Okamoto H, Nishida S, Todo H, Sakakura Y, Iida K, Danjo K. Pulmonary genedelivery by chitosan-pDNA complex powder prepared by a supercritical carbondioxide process. J Pharm Sci 2003; 92:371-379.
52. Sellers SP, Clark GS, Sievers RE, Carpenter JF. Dry powder of stable formulationsfrom aqueous solutions prepared using supercritical CO2-assisted aerosolization. J Pharm Sci 2001; 90:785-797.
53. Sievers RE, Quinn BP, Huang ETS, Cape SP, Algarov D, Rinner L, Villa JA. Stabilization, micronization, and coating of proteins, peptides, antibodies andenzymes by CO2-assisted nebulization with bubble dryer. Proceedings of the Protein Stability Conference, Breckenridge, Colorado, 2003:25.
54. Sievers RE, Milewski PD, Sellers SP, Miles BA, Korte BJ, Kusek MD, Clark GS, Mioskowski B, Villa JA. Supercritical and near-critical carbon-dioxide assistedlow-temperature bubble drying. Ind Eng Chem Res 2000; 39:4831-4836.
55. Sievers RE, Huang ETS, Villa JA, Kawamoto JK, Evans MM, Brauer PR. Lowtemperaturemanufacturing of fine pharmaceutical powders with supercriticalfluid aerosolization in a bubble dryer. Pure Appl Chem 2001; 73:1299-1303.
56. Martin TM, Bandi N, Shultz R, Roberts CB, Kompella UB. Supercritical fluidtechnology-derived budesonide and budesonide-pla microparticles for respiratorydelivery. AAPS Pharm Sci 2001:3.
57. Wilkins S, Shekunov BY, York P. Theophylline: ethylcellulose co-precipitatesformed by solution enhanced dispersion by supercritical fluids (SEDS) andsolvent co-evaporation-structural analysis by synchrotron powder X-ray diffraction. AAPS Pharm Sci 2001; 3: 1136.
58. Zhou H, Lengsfe1d C, Claffey DJ, Ruth JA, Hybertson B, Randolph TW, Ng K-Y, Manning MC. Hydrophobic ion pairing of isoniazid using a prodrugapproach. J Pharm Sci 2002; 91: 1502–1511.
59. Shekunov BY, Edwards AD. Crystallization and plasticization and of poly (L-1actide) by carbon dioxide. Accepted for publication in Proceedings of the 6th International Symposium on Supercritical Fluids, April 28–30, Versailles, France.
60. Edwards AD, Shekunov BY, Forbes RT, Grossmann JG, York P. The structureand morphology ofpoly(L-lactide) particles formed by spray-drying and solutionenhanced dispersion by supercritical fluids (SEDS). Proceedings of the 18th Pharmaceutical Technology Conference, Utrecht, Netherlands, 1999; 1:37-44.
61. Owens JL, Anseth KS, Randolph TW. Compressed antisolvent precipitation and photopolymerization to form highly cross-linked polymer particles. Macromolecules 2002; 35:4289-4296.
62. Mandel FS, Wang JD. Pharmaceutical material production via supercritical fluids employing the technique of particles from gas-saturated solutions. Proceedings of the 7th Meeting on Supercritical Fluids, Antibes, France, 2000:35-45.
63. Howdle SM, Watson MS, Whitaker MJ, Popov VK, Davies MC, Mandel FS, Wang JD, Shakesheff KM. Supercritical fluid mixing: preparation of thermallysensitive polymer composite containing bioactive materials. J Chem Soc Chem Commun 2001:109-110.
64. Lee K, Gould G. Aerogel powder therapeutic agents. International patent publication WO 02/051389, 2002.
65. Shekunov BY, Hanna M, York P. Crystallization process in turbulent supercriticalflows. J Cryst Growth 1999; 198/199:1345-1351.
66. Shekunov BY, Baldyga J, York P. Particle formation by mixing with supercriticalantisolvent at high Reynolds numbers. Chem Eng Sci 2001; 56:1-13.
67. Bristow S, Shekunov T, Shekunov BY, York P. Analysis of the supersaturationand precipitation process with supercritical CO2. J Supercrit Fluids 2001; 21:257-271.
68. Ganser GH. A rational approach to drug prediction of spherical and nonsphericalparticles. Powder Technol1993; 77:143-152.
69. Bristow SC, Shekunov BY, York P. Solubility analysis of drug compounds insupercritical carbon dioxide using static and dynamic extraction systems. IndEng Chem Res 2001; 40:1732-1739.
70. French DL, Edwards DA, Niven RW. The influence offormulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 1996;27:769-783.
71. Li WI, Perzl M, Heyder J, Langer R, Brain JD, Englmeier KH, Niven RW, Edwards DA. Aerodynamics and aerosol particle deaggregation phenomena in model oral-pharyngeal cavities. J Aerosol Sci 1996; 27:1269-1286.
72. Kendall K, Stainton K. Adhesion and aggregation of fine particles. Powder Technol 2001; 121:223-229.
73. Rowe RC. Interaction of lubricants with microcrystalline cellulose and anhydrouslactose-a solubility parameter approach. Int J Pharm 1988; 41:223-226.
74. Valverde JM, Ramos A, Castellanos A, Watson PK. The tensile strength of cohesive powders and its relationship to consolidation, free volume and cohesivity. Powder Technol 1998; 97:237-245.
75. Louey MD, Mulvaney P, Stewart PJ. Characterisation of adhesion lactosecarriers using atomic force microscopy. J Pharm Biomed Anal 2001; 25:559-567.
76. Shekunov BY, Kippax P, Jones L, Rehman M, York P. Analysis of dry powdersaerosols using laser diffraction. Proceedings of the American Association of Pharmaceutical Sciences Annual Conference, Denver, AAPS Pharm Sci 2001;3:108.